Showing 24,381 - 24,400 results of 25,042 for search '"CD"', query time: 0.13s Refine Results
  1. 24381
  2. 24382
  3. 24383
  4. 24384
  5. 24385
  6. 24386
  7. 24387
  8. 24388
  9. 24389

    Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-... by Caroline J. Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, Joy Poroye, Daniella Forman Faden, Lillian Xie, Rui Feng, Barbara White, Victoria P. Werth

    Published 2025-01-01
    “…Biopsies show elevated inflammatory cells such as CD4+ T cells, dendritic cells, and cytokines. Lenabasum, a selective cannabinoid receptor 2 agonist, has demonstrated significant benefits in treating autoimmune skin diseases. …”
    Get full text
    Article
  10. 24390
  11. 24391
  12. 24392
  13. 24393
  14. 24394

    Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor by Junying Wang, Mengping Chen, Jinxing Jiang, Yike Wan, Xin Li, Minyue Zhang, Fei Xiao, Lu Zhong, Hua Zhong, Zhaoyu Qin, Jian Hou

    Published 2025-01-01
    “…The role of USP7 in modulating SEL sensitivity was analyzed in MM cell lines, primary CD138+ cells, and xenograft mouse models. Results SEL promotes the degradation of XPO1 in MM cells through the ubiquitin–proteasome pathway. …”
    Get full text
    Article
  15. 24395

    Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

    Published 2023-01-01
    “…Using flow cytometry, we identified an influx of CD8+ T cells with a less exhausted phenotype in both the ISV-targeted primary and the distant secondary tumor following the combination of secondary tumor EBRT or TRT with primary tumor ISV.Conclusions We report a novel use for low-dose RT, not as a direct antitumor modality but as an immunomodulator capable of driving and expanding antitumor immunity against metastatic tumor sites following ISV.…”
    Get full text
    Article
  16. 24396
  17. 24397
  18. 24398
  19. 24399
  20. 24400